| pubmed-article:12176787 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12176787 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:12176787 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:12176787 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:12176787 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:12176787 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:12176787 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:12176787 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:12176787 | pubmed:dateCreated | 2002-8-14 | lld:pubmed |
| pubmed-article:12176787 | pubmed:abstractText | The cisplatin and gemcitabine (GC) regimen is usually administered as a 4- or 3-week schedule; however, the best schedule to use is still unclear. We therefore started a randomized phase II trial to compare toxicity and dose intensity (DI) between these two GC schedules. | lld:pubmed |
| pubmed-article:12176787 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12176787 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12176787 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12176787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12176787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12176787 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12176787 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12176787 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12176787 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:SantoroAA | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:AlloisioMM | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:AntonelliGG | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:SalaAA | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:RavasiGG | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:LatteriFF | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:DambrosioMM | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:CavinaRR | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:Soto ParraHH | lld:pubmed |
| pubmed-article:12176787 | pubmed:author | pubmed-author:MorenghiEE | lld:pubmed |
| pubmed-article:12176787 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12176787 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:12176787 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12176787 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12176787 | pubmed:pagination | 1080-6 | lld:pubmed |
| pubmed-article:12176787 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:meshHeading | pubmed-meshheading:12176787... | lld:pubmed |
| pubmed-article:12176787 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12176787 | pubmed:articleTitle | Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. | lld:pubmed |
| pubmed-article:12176787 | pubmed:affiliation | Department of Medical Oncology and Hematology and Division of Thoracic Surgery, Istituto Clinico Humanitas, Rozzano-Milan, Italy. hector.sotoparra@humanitas.it | lld:pubmed |
| pubmed-article:12176787 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12176787 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12176787 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12176787 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12176787 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12176787 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12176787 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12176787 | lld:pubmed |
